Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 12, 2006, Pages 1103-1110

  Martin, Lee J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha synuclein; Apoptosis; DNA damage; Mitochondria; Nitric oxide synthase; p53; Permeability transition pore

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; BENZODIAZEPINE RECEPTOR; CALCIUM; CYCLOPHILIN; CYCLOPHILIN D; CYTOCHROME C; DNA; ENDONUCLEASE; ENDONUCLEASE G; MITOCHONDRIAL PROTEIN; PERIPHERAL BENZODIAZEPINE RECEPTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; VOLTAGE GATED CHANNEL FORMING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL AGING; CELL DEATH; CELL DEGENERATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HUMAN; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 33845353404     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000248541.05552.c4     Document Type: Review

References (74)

1. Nicholls DG. Mitochondrial function and dysfunction in the cell: Its relevance to aging and aging-related disease. Intl J Biochem Cell Biol 2002;34:1372-81
2. Martin LJ, Al-Abdulla NA, Brambrink AM, et al. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998;46:281-309
3. Choi DW. Cellular defences destroyed. Nature 2005;433:696-98
4. Olney JW. Brain lesion, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:366-68
5. Brown MR, Sullivan PG, Geddes JW. Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria. J Biol Chem 2006;281:11658-68
6. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn of evolutionary medicine. Annu Rev Genet 2005;39:359-407
7. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:548
8. Martin LJ, Liu Z. DNA damage profiling in motor neurons: A single-cell analysis by comet assay. Neurochem Res 2002;27:1089-100
9. Ameisen JC. On the origin, evolution, and nature of programmed cell death: A timeline of four billion years. Cell Death Diff 2002;9:367-93
10. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Ann Rev Neurosci 1997;20:245-67
11. Cory S, Adams JM. The bcl-2 family: Regulators of the cellular life-or-death switch. Nat Rev 2002;2:647-56
12. Lorenzo HK, Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS Lett 2004;557:14-20
13. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of bax channel-forming activity by bcl-2. Science 1997;277:370-72
14. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-31
15. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem 2000;275:12321-25
16. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for bcl-2 regulation of apoptosis. Science 1997;275:1132-36
17. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-46
18. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89
19. Vander Heiden MG, Chandel NS, Williamson EK, et al. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997;91:627-37
20. Wei MC, Zong W-X, Cheng EH-Y, et al. Proapoptotic Bax and Bak: A requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30
21. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92
22. 2+: A control point for apoptosis. Science 2003;300:135-39
23. Jones JM, Datta P, Srinivasula SM, et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder mnd2 mutant mice. Nature 2003;425:721-27
24. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005;15:2099-111
25. Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002;419:367-74
26. Mate MJ, Ortiz-Lombardia M, Boitel B, et al. The crystal structure of the mouse apoptosis-inducing factor AIF. Nat Struct Biol 2002;9:442-46
27. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341:233-49
28. Rostovtseva TK, Tan W, Colombini M. On the role of VDAC in apoptosis: Fact and fiction. J Bioenerg Biomembr 2005;37:129-42
29. van Gurp M, Festjens N, van Loo G. Mitochondrial intermembrane proteins in cell death. Biochem Biophys Res Commun 2003;304:487-97
30. Crompton M. Mitochondria and aging: A role for the permeability transition? Aging Cell 2004;3:3-6
31. Levrero M, De Laurenzi V, Costanzo A, et al. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000;113:1661-70
32. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003;302:1036-38
33. Erster S, Moll UM. Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun 2005;331:843-50
34. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-14
35. Leu JI-J, Dumont P, Hafey M, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004;6:443-50
36. Soong NW, Hinton DR, Cortopassi G, Arnheim N. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 1992;2:318-23
37. Corral-Debrinski M, Horton T, Lott MT, et al. Mitochondrial DNA deletions in human brain: Regional variability and increase with advanced age. Nat Genet 1992;2:324-29
38. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Ann Rev Neurosci 1999;22:123-44
39. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: Variations by age, gender and race ethnicity. Am J Epidemol 2003;157:1015-22
40. Lowe J, Lennox G, Leigh PN. Disorders of movement and system degeneration. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. London: Arnold, 1997:281-366
41. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501
42. Schapira AHV. Etiology of Parkinson's disease. Neurology 2006;66 (suppl 4):S10-S23
43. Martin LJ. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev Neurosci. In press
44. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminals. J Neurosci 1988;8:2804-15
45. Murphy DD, Rueter SM, Trojanowski JQ, Lee VMY. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000;20:3214-20
46. Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401-10
47. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005;14:3477-92
48. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004;101:9103-108
49. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: Clinical and molecular genetic study. Lancet 2004;364:875-82
50. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat Genet 2006;38:515-17
51. Kraytsberg Y, Kudryavtseva E, McKee AC, et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 2006;38:518-20
52. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science 1983;219:979-80
53. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36:2503-508
54. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med 2003;9:360-65
55. Liss B, Haeckel O, Wildmann J, et al. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci 2005;8:1742-51
56. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF. Genetic mouse models of Huntington's and Parkinson's diseases: Illuminating but imperfect. Trends Neurosci 2004;27:691-97
57. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006;26:41-50
58. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-700
59. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: A review of the evidence. Neuropathol Appl Neurobiol 2001;27:257-74
60. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002;40:543-51
61. Siklos L, Engelhardt J, Harati Y, et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 1996;39:203-16
62. Beal MF. Oxidatively modified protein in aging and disease. Free Radic Biol Med 2002;32:797-803
63. Browne SE, Bowling AC, Baik MJ, et al. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem 1998;71:281-87
64. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46:787-90
65. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000;123:1339-48
66. Comi GP, Bordoni A, Salani S, et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol 1998;43:110-16
67. Borthwick GM, Taylor RW, Walls TJ, et al. Motor neuron disease in a patient with a mitochondrial tRNAIle mutation. Ann Neurol 2006;59:570-74
68. Mawrin C, Kirches E, Krause G, et al. Single-cell analysis of mtDNA levels in sporadic amyotrophic lateral sclerosis. Neuroreport 2004;15:939-43
69. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459-71
70. Martin LJ, Liu Z. Opportunities for neuroprotection in ALS using cell death mechanism rationales. Drug Discov Today 2004;1:135-43
71. Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ. Cell and tissue microdissection in combination with genomic and proteomic profiling. In: Zaborszky L, Wouterlood FG, Lanciego JL, eds. Neuroanatomical Tract-Tracing 3. Molecules, Neurons, and Systems. New York: Springer, 2006:109-41
72. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis 2000;7:613-22
73. Martin LJ, Liu Z. Injury-induced spinal motor neuron apoptosis is preceded by DNA single-strand breaks and is p53- and Bax-dependent. J Neurobiol 2002;50:181-97
74. Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: Mechanisms of mitochondropathy and cell death. J Comp Neurol 2007;500:20-46